Life Edit Therapeutics, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jun 2039
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 2, 2027The maintenance fee for RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use (US 11,859,181) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Sep 12, 2027The maintenance fee for RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use (US 11,926,843) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 2 fees due Nov 14, 2027
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,338,455 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · High confidence | In force | High confidence | |
| US 11,926,843 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · High confidence | In force | High confidence | |
| US 12,188,018 | Polypeptides Useful for Gene Editing and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 11,162,114 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · High confidence | In force | High confidence | |
| US 11,981,916 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 12,252,706 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · Low confidence | In force | Low confidence | |
| US 11,859,181 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · High confidence | In force | High confidence | |
| US 11,981,940 | DNA Modifying Enzymes and Active Fragments and Variants Thereof and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 12,188,061 | Nucleic Acid Molecules Encoding DNA Modifying Enzymes and Active Fragments and Variants Thereof and Compositions Comprising the Same In force · Medium confidence | In force | Medium confidence | |
| US 12,188,062 | DNA Modifying Enzymes and Active Fragments and Variants Thereof and Methods of Use In force · Medium confidence | In force | Medium confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
10 pending · 3 abandoned